OVARIAN CANCER and US

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Thursday, August 30, 2012

ongoing: (gyn cancers) ChemoFx® PRO - A Post-Market Data Collection Study - Full Text View - ClinicalTrials.gov



ChemoFx® PRO - A Post-Market Data Collection Study - Full Text View - ClinicalTrials.gov

ongoing: A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study - Full Text View - ClinicalTrials.gov



A Study of ChemoFx® Chemoresponse Assay in Solid Tumors - ChemoFx® Registry Study - Full Text View - ClinicalTrials.gov

ongoing: Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov



Carboplatin and Paclitaxel With or Without Bevacizumab After Surgery in Treating Patients With Recurrent Ovarian Epithelial Cancer, Primary Peritoneal Cavity Cancer, or Fallopian Tube Cancer - Full Text View - ClinicalTrials.gov

An eClinical trial system for cancer that integrates with clinical pathways and electronic medical records



An eClinical trial system for cancer that integrates with clinical pathways and electronic medical records:

Background
Various information technologies currently are used to improve the efficiency of clinical trials. However, electronic medical records (EMRs) are not yet linked to the electronic data capture (EDC) system. Therefore, the data must be extracted from medical records and transcribed to the EDC system. Clinical pathways are planned process patterns that are used in routine clinical practice and are easily applicable to the medical care and evaluation defined in a trial protocol. However, few clinical pathways are intended to increase the efficiency of clinical trials.

Purpose
Our purpose is to describe the design and development of a new clinical trial process model that enables the primary use of EMRs in clinical trials by integrating clinical pathways and EMRs.

Methods
We designed a new clinical trial model that uses EMR data directly in clinical trials and developed a system to follow this model. We applied the system to an investigator-initiated clinical trial and examined whether all data were extracted correctly. At the protocol development stage, our model measures endpoints based on clinical pathways with the same diagnosis. Next, medical record descriptions and the format of the statistical data are defined. According to these observations, screens for entry of data, which are used both in clinical practice and for study, are prepared into EMRs with an EMR template, and screens are prepared for data checks on our EMR retrieval system (ERS). In an actual trial, patients are registered and randomly assigned to a protocol treatment. The protocol treatment is executed according to clinical pathways, and the data are recorded to EMRs using EMR templates. The data are checked by a local data manager using reports created by the ERS. After edit checks and corrections, the data are extracted by the ERS, archived in portable document format (PDF) with an electronic signature, and transferred in comma-separated values (CSV) format to a coordinating centre. At the coordinating centre, the data are checked, integrated, and made available for a statistical analysis.

Results
We verified that the data could be extracted correctly and found no unexpected problems.

Limitation
To execute clinical trials in our system, the EMR template and efficient ERSs are required. Additionally, to execute multi-institutional clinical trials, it is necessary to create templates appropriate for EMRs at all participating sites and for the coordinating centre to validate local templates and procedures.

Conclusion
We proposed and pilot tested a new eClinical trial model. Because our model is integrated with routine documentation of clinical practice and clinical trials, redundant data entries were avoided and the burden on the investigator was minimised. The reengineering of the clinical trial process would facilitate the establishment of evidence in the future.

Wednesday, August 29, 2012

Vancouver, BC: The Effect of Direct-to-Consumer Genetic Tests on Anticipated Affect and Health-Seeking Behaviors: A Pilot Survey | Abstract



The Effect of Direct-to-Consumer Genetic Tests on Anticipated Affect and Health-Seeking Behaviors: A Pilot Survey | Abstract

Gynecologic Oncology - Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer



Gynecologic Oncology - Identification of the optimal pathway to reach an accurate diagnosis in the absence of an early detection strategy for ovarian cancer

Abstract

Objectives

There is a lack of knowledge about the health care events experienced by individual patients that lead to a definitive diagnosis of ovarian cancer (OC). The goal of this study was to describe the various pathways and to identify an optimal path to accurate diagnosis.

Methods

Women who were referred to gynecologic oncology for a suspected OC were enrolled to this study. Medical records (MRs) from all health care providers were obtained from the time the patient recalled first suspecting a health issue through the time of diagnosis to build a decision tree model. A Monte Carlo simulation was conducted of 83,000 patients to identify the optimal pathway to reach diagnosis.

Results

In the Monte Carlo simulation, gynecologic oncologists and gynecologists accounted for the most efficient diagnosis in over 37.9% and 29.2% of suspected OC cases, respectively, in terms of the least amount of time to reach diagnosis. Gynecologic oncologists were further associated with the fewest health care visits needed to reach diagnosis in 37% of the simulation cases; however, 23% of trials were indifferent to any specific provider.

Conclusions

The decision tree provides a more comprehensive view of the complexity in reaching an accurate diagnosis of OC. This analysis was able to identify the health care utilization patterns that underlie the events that occur to reach an accurate diagnosis in the setting of a suspected OC, and was able to identify the most efficient pathways that utilize the fewest health care resources in the least amount of time.

Highlights

► The Monte Carlo simulation found differences in efficiency to reach diagnosis in terms of both time and fewest healthcare visits
► Gynecologic oncologists were the most rapid and efficient entry point for patients to reach diagnoses in the Monte Carlo simulation
► Many healthcare resources (provider visits, tests and assessments) are utilized in the absence of early detection strategies for ovarian cancer

2012 (understanding) Abdominal and Pelvic CT



Abdominal and Pelvic CT

Current Opinion in Oncology- The management of small-cell carcinomas of the gynecologic tract



http://mobile.journals.lww.com/co-oncology/_layouts/oaks.journals.mobile/abstractviewer.aspx?year=2012&issue=09000&article=00016


Sent from my iPhone

CEBP: Oophorectomy and Breast Cancer inBRCA Mutation Carriers—Letter




Oophorectomy and Breast Cancer inBRCA Mutation Carriers—Letter
 Authors

The article by Kotsopoulos and colleagues (1) shows that oophorectomy significantly decreased the incidence of breast cancer in carriers of deleterious BRCA mutations, with OR, 0.52 [95% confidence interval (CI), 0.40–0.66]. This is an important result. The authors, however, wrongly interpreted their results writing that "women who underwent surgical menopause had a 48% decrease in the risk of developing breast cancer." An OR, in fact, is a good estimate of the relative risk (i.e., the risk ratio) only if the disease is rare, but in mutation carriers, the disease is very frequent. The source population actually included about 4,000 cases of 5,000 women, a proportion fairly consistent with the estimated penetrance of BRCA mutations. With such a large proportion of cases in the source population, the unbiased risk ratio could be of the order of 0.67, corresponding to 33% decrease in breast cancer risk, still a major effect. The same flawed interpretation was present in several previous articles from the same group.

Disclosure of Potential Conflicts of Interest

There are no potential conflicts of interest.

  • Received May 18, 2012.
  • Accepted May 22, 2012.

Reference

  1.  



Sent from my iPhone

CEBP: Lipid Profiles and Risk of Breast and Ovarian Cancer in the Swedish AMORIS Study



http://m.cebp.aacrjournals.org/content/21/8/1381.short


Sent from my iPhone

BMJ Group blogs: BMJ » Blog Archive » Martin Wiseman, Kathryn Allen, and Rachel Thompson: Weighing the evidence on cancer prevention



http://blogs.bmj.com/bmj/2012/08/28/martin-wiseman-kathryn-allen-and-rachel-thompson-weighing-the-evidence-on-cancer-prevention/


Sent from my iPhone

ScienceDirect.com - Gynecologic Oncology - Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients




Prolonged postoperative venous thrombo-embolism prophylaxis is cost-effective in advanced ovarian cancer patients


Abstract

Objective

The purpose of this study was to investigate the cost-effectiveness of prolonged prophylaxis with enoxaparin in high-risk surgical patients with ovarian cancer. In addition, we sought to quantify the impact of prolonged prophylaxis (PP) on the incidence of venous thromboembolism (VTE), its related complications, and overall patient survival.

Methods

A Markov decision analytic model was used to estimate the costs, resource allocation and outcomes associated with the prolonged use of enoxaparin, for a total of four weeks after surgery, in patients undergoing primary debulking surgery for stage IIIC ovarian cancer. We estimated incremental cost per quality-adjusted life-year (QALY) at one and five year intervals; the estimated reduction in VTE episodes, bleeding episodes, and survival at the five year interval for a simulated cohort of 10,000 women.

Results

The incremental cost effectiveness ratio (ICER) for prolonged prophylaxis (PP) was $5236/QALY and $-1462/QALY at one and five years respectively. For patients receiving PP, the model estimated a 12% reduction in the clinically evident VTE episodes and a higher five-year survival (31.61% vs. 29.96%; p < 0.0001). Resource allocation analysis reveals that 95% of initial investment cost of prolonged enoxaparin is recovered within one year.

Conclusions

In ovarian cancer patients undergoing open abdominal surgery, prolonged VTE prophylaxis not only improves patient outcomes, but is also a cost saving strategy when modeled over five years. A significant reduction in the episodes of VTE and a higher overall survival warrants consideration for the routine use of PP in this patient population.


Highlights

► Prolonged VTE prophylaxis is a cost saving strategy when modeled over five years in post-operative ovarian cancer patients. ► Our model estimates improved overall survival and decreased number of venous thromobembolic events with prolonged prophylaxis.

Keywords

  • Prolonged 

BMC Cancer | Abstract | Derivation and characterization of matched cell lines from primary and recurrent serous ovarian cancer



http://www.biomedcentral.com/1471-2407/12/379/abstract


Sent from my iPhone

Tuesday, August 28, 2012

Non-adherence patient care.......



"....Non-adherence is a problem but it is not the patient's problem. It is really an indication that something has gone wrong in the process of delivering care..."

http://www.google.ca/reader/i/?source=mog&hl=en&gl=ca#stream/feed%2Fhttp%3A%2F%2Fwww.cancerworld.org%2Ffeed.html


Sent from my iPhone

JCO Editorial Accumulating Evidence for the Effect of Chemotherapy on Cognition



http://m.jco.ascopubs.org/content/early/2012/08/26/JCO.2012.43.5776.full.pdf#page=1


Sent from my iPhone

Recommendations for including multiple symptoms as endpoints in cancer clinical trials - 2012 - Cancer



Recommendations for including multiple symptoms as endpoints in cancer clinical trials 

A report from the ASCPRO (Assessing the Symptoms of Cancer Using Patient-Reported Outcomes) Multisymptom Task Force




Sent from my iPhone

BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer - Grisham - 2012 - Cancer - Wiley Online Library




BRAF Mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer

Article first published online: 28 AUG 2012

DOI: 10.1002/cncr.27782

Cover image for Vol. 118 Issue 17



Sent from my iPhone

JCP High grade serous carcinoma of the ovary with a yolk sac tumour component in a postmenopausal woman: report of an extremely rare phenomenon



http://m.jcp.bmj.com/content/65/9/853.short?rss=1


Sent from my iPhone

Is long-term weight loss possible after menopause?



http://www.sciencedaily.com/releases/2012/08/120828093238.htm?utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+sciencedaily+%28ScienceDaily%3A+Latest+Science+News%29&utm_content=Google+Reader


Sent from my iPhone

Mandated "GMO Food" Disclosure: Labeling for Thee but Not for Me - Forbes





Labeling for products that meet the USDA-NOP s...

Labeling for products that meet the USDA-NOP standards (Photo credit: Wikipedia)




Sent from my iPhone

JOP : Attitudes of Patients With Cancer About Personalized Medicine and Somatic Genetic Testing



http://m.jop.ascopubs.org/content/early/2012/08/07/JOP.2012.000626


Sent from my iPhone

Practical Guidance: The Use of Social Media In Oncology Practice



http://m.jop.ascopubs.org/content/early/2012/07/17/JOP.2012.000610


Sent from my iPhone

Journal of Oncology Practice-Do High Symptom Scores Trigger Clinical Actions? An Audit After Implementing Electronic Symptom Screening



Do High Symptom Scores Trigger Clinical Actions? An Audit After Implementing Electronic Symptom Screening

 Authors
  1. Daryl Bainbridge, PhD
  1. McMaster University; and Juravinski Cancer Centre, Hamilton, Ontario, Canada
  1. Corresponding author: Hsien Seow, PhD, Cancer Care Ontario Research Chair in Health Services Research, Assistant Professor, Department of Oncology, McMaster University, 699 Concession St, 4th floor, Rm 4-229, Hamilton, Ontario L8V 5C2, Canada; e-mail: seowh@mcmaster.ca.

Abstract

Purpose: Standardized, electronic, symptom assessment is purported to help identify symptom needs. However, little research examines clinical processes related to symptom management, such as whether patients with worsening symptoms receive clinical actions more often. This study examined whether patient visits with higher symptom scores are associated with higher rates of symptom documentation in the chart and symptom-specific actions being taken.

Methods: Retrospective chart reviews on cancer patient visits at a regional cancer center. An electronic Edmonton Symptom Assessment Scale (ESAS), a validated tool to measure symptoms, was implemented center-wide to standardize symptom screening at every patient visit. The independent variable was ESAS scores for pain and shortness of breath, categorized by severity: 0 (none), 1-3, 4-6, 7-10 (severe). Outcomes included symptom documentation in the chart on the visit date and symptom-related action(s) taken within 1 week.

Results: Nine hundred twelve visits were identified. Pain and shortness of breath were documented in 51.8% and 29.7% of charts, and a related-action occurred in 16.9% and 3.9% of charts, respectively. As ESAS severity score category increased from none to severe, the proportion of visits with pain documented increased significantly (36.9%, 49.2%, 55.2%, and 71.4%; P < .001). Likewise, as ESAS score severity increased, the proportion of visits with a pain-related action increased significantly (4.2%, 10.6%, 21.3%, and 37.0%; P < .001). Trends were similar for shortness of breath.

Conclusion: Results show a positive association between higher symptom scores and higher rates of documentation and clinical actions taken. However, symptom-related actions were documented in a minority of visits in which symptoms were noted as severe.




Sent from my iPhone

JOP : Journal of Oncology Practice - patient/physician discussions regarding cancer costs (abstract)



"Conclusion: Patients' comfort with and desire to discuss cancer costs exceed that of oncologists, suggesting a need to educate oncologists on this important topic. A patient's desire to understand treatment-associated cost does not equate with a desire for cost to influence medical decision making."

http://m.jop.ascopubs.org/content/8/4/e50.short?rss=1


Sent from my iPhone

Journal of negative results article



During an interview with Journal of Negative Results in BioMedicine (JNRBM), Dr Haiko Sprott(below) provides some interesting and thought-provoking views on why the publication of negative results is valuable to the scientific community. Dr Sprott is Head of the Pain Clinic Basel, Switzerland, and carries out research into chronic pain, pain genes and multimodal pain therapy. He is also an Editorial Board member forJNRBM.



Sent from my iPhone